Sorry, no posts matched your criteria.
Exubera Inhaled Insulin: Reported & Suspected Risks for Diabetics
Exubera inhaled insulin news and information on the FDA approved diabetes drug
- Categories:
- Alkermes (6)
- American Diabetes Ass’n (3)
- Amylin Pharmaceuticals (1)
- Apidra (1)
- Aradigm Corp. (1)
- Avandia (3)
- Avandia Heart Attacks (3)
- Avandia Injuries (3)
- Avandia v. Exubera (3)
- Breeze Study (6)
- Byetta (1)
- Diabetes Recall Alerts (2)
- Diabetes Research (57)
- Drug Litigation (12)
- Eli Lilly & Co. (11)
- Exubera - Canada (5)
- Exubera - EU Approval (15)
- Exubera - FDA Approval (67)
- Exubera - Global Sales (11)
- Exubera - India (1)
- Exubera - Middle East (1)
- Exubera - Nektar (59)
- Exubera - Pfizer (172)
- Exubera - Pulmonary Issues (75)
- Exubera - Sales (101)
- Exubera - Saudi Arabia (1)
- Exubera - Spain (1)
- Exubera - Terre Haute (1)
- Exubera Ads (2)
- Exubera Cost (27)
- Exubera Education (6)
- Exubera Layoffs (1)
- Exubera Marketing (34)
- Exubera News (198)
- Exubera Risks (80)
- Exubera: Diabetes Treatment (128)
- Exubera: Formulary (16)
- Exubera: Insulin & Drug Sales (107)
- Exubera: Insurance Coverage (24)
- Exubera: Physician Comments (39)
- Exubera: Sanofi-Aventis (11)
- Exubera: Smoking (9)
- Exubera: Type 1 Diabetes (96)
- Exubera: Type 2 Diabetes (86)
- Generex Biotechnology Corp. (1)
- Ind. (1)
- Inhaled Insulin - Scotland (1)
- Januvia - Merck (4)
- Januvia: FDA Approval (1)
- Lantus (1)
- MannKind Corp. (13)
- Novo-Nordisk (14)
- U.K. NICE Exubea Inhaled Insulin Analysis (8)
- Uncategorized (17)
- Archives:
|
More blogs about Diabetes, Type 1 Diabetes, Type 2 Diabetes, Insulin, Exubera, Pfizer, Nektar. Januvia 
|
Blogroll
Diabetes Drug Companies
Diabetes News
Get The RSS Feed
- Meta:
Recently Posted
- Pfizer, Nektar: Diabetics Who Used Exubera Developed Lung Cancer
- Pfizer Laying Off 660 Exubera Inhaled Insulin Workers From Terre Haute Plant
- Novo-Nordisk Opts to Stop Inhaled Insulin Development
- Novo-Nordisk, Pfizer Settle Patent Lawsuit Over Inhaled Insulin
- Go Insulin Injectable Insulin Ads From Sanofi - Spending $1.3B in Exubera Deal Money
- Alkeremes CEO Warns AIR Inhaled Insulin With Lilly May Affect Lung Function
- Pfizer Stops Exubera Inhaled Insulin Sales, Citing Financial Reasons
- Apparent Pfizer Employee Discloses Exubera Production Issues
- Nektar's CEO: Exubera Inhaled Insulin "Not Strategically Relevant"
- Pfizer's Senior Middle East Manager Discusses Exubera and Diabetes
- Pharma Equity Analyst Calls Exubera a 'Sepctacular Flop'
- Joslin Diabetics Clinic Doctor Cautions About Oral Insulin Delivery Dosing
- Pfizer Exubera Ad, Not
- V.A. Exubera Formulary Conditions: Strange Stuff
- Spain's National Health System Financing Exubera for Diabetics
- Exubera: 3rd Most 'Consumer-Friendly' Drug Name
- Pfizer Exubera Safety Study of 2+ Years: Type 1 Diabetics
- Canadian Health Officials Still Weighing Exubera Approval
- Pfizer Detail Rep Appears To Have Disclosed Patient FEV Decrease, Lung Function Problems
- Money Manager at Legg Mason Praises Mannkind's Technosphere Inhaled Insulin Device
- Pfizer to Present at ADA Annual Scientific Sessions This Week
- ADA President: "My Job [Is] To Talk People Out Of" Using Exubera
- Avandia Risks v. Exubera Risks
- Did Pfizer Spend Money On A Survey That Has Doctors Praising Exubera Inhaled Insulin?
- NEJM Article Slams Pfizer On Exubera DTC Advertising When Drug Safety Studies Are Still Pending
- Canadian Professor Gets Funding For Inhaled Insulin Particle Technology Research
- Dubai Approves Exubera Inhaled Insulin
- Pfizer Will Post 1Q Earnings Friday: Exubera Sales Expected to Underperform
- A.G. Edwards Analyst Reports on Sluggish Exubera Sales
- Motley Fool Compares Mannkind's Technosphere with Pfizer's Exubera Inhaled Insulin
- Novo Nordsik Scales Back Claims Against Pfizer in Inhaled Insulin Patent Lawsuit
- NYT Reporter Cites Analysts and Doctors in Coverage of Poor Exubera Sales
- Diabetic Reporter Quits Using Exubera: "Blood Sugars Fluctuated Wildly"
- Exubera Sales Totaled $18.9M in 2006 For Pfizer
- Pfizer Exubera Inhaled Insulin Supply Far Exceeds Demand
- Doctors and Insurers Reluctant to Approve Exubera Inhaled Insulin Scrips
- Virginia TV Reporter Concludes Exubera is 'Gatherin Dust'
- Diabetic Report: Exubera "Inhaler Was Large And Awkward"
- More Complaints By A Pfizer Sales Rep Over Exubera Issues?
- Pfizer Did Not Advertise Exubera in ADA 2007 Diabetes Resource Guide
- Exubera Sales: Did Pfizer Fund an Advertorial in WebMD's Medscape With Misleading Information?
- "Our Market Research...[Exubera] Profit Margins Will Greatly Overshadow" Pfizer Production Costs
- Exubera Drug Approvals: A Global Round-Up
- Pfizer Seeks Exubera Inhaled Insulin Launch in India
- Nektar Reports That Exubera-Related Revenue Was $110M For 2006
- BrandWeek Report Critiques Pfizer For 'Billion-Dollar Bong'
- Two Year Inhaled Insulin Trial Underway, Recruiting Patients in Scotland
- Pfizer's Exubera Inhaled Insulin Still Not Approved in Canada
- Pfizer Launching TV Exubera Sales Campaign Targeting Diabetics
- Drug Sales Team Message Board Post Suggests Pfizer Concerned Company Info. Being Leaked
- NEJM Article Analyzing Pfizer's Exubera Inhaled Insulin: A Case Vignette
- India May Get Inhaled Insulin Approval Within 2 Years
- More Reports of Previous Exubera Inhaler Problems?
- Study: Number of Diabetics Ineligible for Exubera Inhaled Insulin Should Double After 7 years
- Pfizer Spokesman: No Plans to Make Protein-Based Drugs Like Exubera in Mich. Plants
- Exubera Marketing Campaign Launched by Pfizer Using Controversial VNR's
- Pfizer Layoffs Should Not Affect Mich. Exubera Packaging Plant
- Pfizer Layoffs: How Much Will Drugmaker Outsource R&D?; Are Exubera Sales Hurt By Force Reduction?
- Pfizer Closing 3 U.S. Research Sites, Slashing 10,000 Jobs; Little Mention of Exubera
- Pfizer Exubera Manufacturing Employees Like MySpace
- Reporter Highlights Opposition By Doctors, Diabetics to Pfizer Exubera Inhaled Insulin
- Report: More Pfizer Layoffs Predicted, Acquisitions Anticipated
- Study Claims Oral Insulin Delivery Achieved in Rats Using Nano-particles
- More Competition to Pfizer's Exubera: Alkeremes and Eli Lilly & Co. Extend Inhaled Insulin Development Deal
- Picture of Novo Nordisk AERx Inhaled Insulin: Big, Bulky Device Like Pfizer Exubera Unit
- United Arab Emirates Gives Conditional Approval For Pfizer's Exubera
- Diabetics Critique Exubera
- Reporter Compares Mannkind's Technosphere To Pfizer's Exubera Inhaled Insulin
- Reporter Says Pfizer's Exubera Sales Are "So Low" That Drugmaker Isn't Reporting Them
- Judge Denies Novo's Attempt to Halt Pfizer's Exubera Sales, Citing Public Interest
- Could Pfizer's Exubera Sales Force Quash The Inhaled Insulin
- Company That Consulted For Nektar on Exubera Will Discuss Pfizer Deal
- Researcher: Exubera May Be Effective, But Expresses "Worrisome Concern" That Exubera May Have On Lung Function
- Nektar's 3Q Results: Heavy Reliance on Exubera Shown
- Was a Potential Exubera Production Risk Inadvertently Disclosed?
- Cost of Exubera Kit Reported By Nektar Investor
- FDA Issues Alert for Counterfeit One Touch Blood Glucose Test Strips
- UBS Analyst Cites Delayed Exubera Launch In Downgrading Pfizer, Inc.
- Pfizer Delays Widespread Exubera Inhaled Insulin Sales, Again
- Analysts Split on Exubera; Doctors Appear To Be The Same
- A Diabetic Teen Critiques Exubera Inhaled Insulin from Pfizer, Inc.
- Pfizer Profit Reported Up; Drugmaker Hopes Exubera Sales Will Increase Revenue
- Some Pfizer Sales Reps Apparently Slamming Exubera
- Doctors Say They Are Excited About Januvia, Others Say Existing Diabetes Drugs Already Effective
- FDA Approval of Januvia Threatens Pfizer Exubera Inhaled Insulin Sales
- Alcohol at Pfizer Exubera Education Event?
- Report on Inhaled Insulin on The Market for Insulin: Is It Worth $2,100?
- Follow-Up Re: 'Taking a Hit' For Pfizer
- Byetta Success Suggests Needle Phobia Is Misplaced
- Exubera Photo Shows Up on Flickr -- 'Taking a Hit' For Pfizer
- Cleveland Clinic Doctor Concerned About Undiagnosed COPD And Exubera
- Exubera Marketing: Are Some Pfizer Sales Reps Criticizing The Inhaled Insulin Launch?
- Pfizer, Inc. Axes High-Level Endocrinology Marketing Executive; Exubera Affected?
- Caution At The FDA, Or Drug Approvals As Usual?
- Nektar Acting CEO Buys Exubera For $20 Co-Pay
- Nektar Acting CEO Disussed Exubera At UBS Conference
- Report: Inhaled Insulins Unlikely to Be Blockbuster Drugs
- Pfizer, Inc. Says Exubera An "Important Source of Revenue Growth"
- Endocrinologists Assess Exubera Inhaled Insulin at Oppenheimer Diabetes Conference
- Univ. of Michigan Lists Pfizer, Inc.'s Exubera on Formulary List
- Nektar CEO's One-Liner On Exubera Safety
- Respected Health Insurance Consultant Slams Pfizer, Inc.
- Oppenheimer Diabetes Conference Examined Exubera Inhaled Insulin
- Exubera Formulary Doubtful: Pa. PPO and TPA Insurer
- Pfizer's CEO Kindler Talks About Exubera at Investment Conference
- Exubera Cost Not Covered By R.I.'s Blue Cross Blue Shield
- Kaiser Permanente Exubera Coverage? It's Anyone's Guess
- Follow-Up: Mannkind Corporation's Inhaled Insulin Study on Type 2 Diabetics Raises An Important Question
- The EASD Conference: Unanswered Exubera Safety Issues
- Pfizer, Inc. Has Exubera Inhaled Insulin Online Webcasts, But They're All Filled Up
- Study Shows Mannkind's Technosphere Inhaled Insulin Could Threaten Pfizer, Inc.'s Exubera
- Pfizer, Inc. Research at European Diabetes Meeting On Exubera and Type 2 Diabetics
- Study Results of Non-Smokers Using Pfizer, Inc's Exubera After Being Exposed to Smoke
- What Kind Of Research Are Stock Analysts Doing On Pfizer, Inc.'s Exubera?
- Scottish Medical Group Concludes Exubera Inhaled Insulin Too Expensive For Diabetics
- Is a Pfizer, Inc. Spokeswoman Being Straight About Exubera Inhaled Insulin?
- WSJ Gives Pfizer, Inc. and Nektar Therapeutics Tech Award for Exubera
- Exubera Praised By Newspaper, But Gets Cost Critique
- Exubera Formulary: A Follow-Up
- Exubera and Aetna, Inc. (AET): A Likely Pattern for Diabetic Insurance Coverage
- Wall Steet Journal Article Highlights Pfizer Inc.'s Exubera Dilemma
- Why Does A Big Mail Order Pharmacy Lack Updated Exubera Information?
- Texas TV Station's Slick Exubera Report Sounds Like Pfizer, Inc. Spin
- Pfizer's Exubera Launch Starts Today
- Report Shows Pfizer, Inc. Funded Congressional Travel: An Rx For Influence?
- Diabetics Need to Be Prepared for Disasters Like Hurricane Ernesto
- Exubera Availability Conundrum?
- Exubera Being Discussed at Drug Delivery Technologies and Dealmaking Conference
- Does Pfizer, Inc. Sales Rep Fear Insurance Coverage Could Hurt Exubera?
- Pfizer, Inc. Files a Response to Novo's Inhaled Insulin Patent Lawsuit
- 2,300 Pfizer Sales Reps Pushing Exubera Inhaled Insulin
- Novo-Nordisk Patent Lawsuit Against Pfizer Over Exubera
- Despite Novo-Nordisk / Pfizer Patent Litigation, Exubera Sales Not Stopped
- Novo Nordisk's Patent Lawsuit Against Pfizer, Inc. Over Inhaled Insulin
- Cost of Exubera Inhaled Insulin in the U.K. Revealed
- New Report: Inhaled Insulin Safety Concerns Affect Diabetes Drug Market
- Doc in Exubera Study Reveals Possible Dilemma for Diabetics
- Pfizer 'Free' Lunches and Exubera Inhaled Insulin Prescriptions
- Is Pfizer's Exubera Insulin Delay Related to Quality Control Problems?
- Smoking and Exubera: Some on Pfizer Sales Team Predict Problems
- Cost of Pfizer Exubera Inhaled Insulin Revealed (Almost)
- Pfizer Sales Rep: Exubera Will Be 'Patient-Driven'; Suggests 'Future Product Improvements'
- Analyzing Pfizer's Delayed Exubera Inhaled Insulin Launch
- Nektar: Pfizer's Exubera Inhaled Insulin Not Available Until Sept. 2006
- Are Pfizer Drug Sales Reps Cynical About Exubera?
- Pfizer Omits Important Exubera Safety Risk Info From Q2 Press Release
- National Pharmacy Doesn't Have Exubera in Stock, Lacks Price Info
- CBC Faux Pas Over Use of Pfizer PR Material in Exubera Report
- Conflict? Pfizer-Funded Canadian Diabetes Doctor Touts Exubera
- Pfizer Feels Pain of BusinessWeek Article on Exubera
Disclaimer: This blog contains news and information about Exubera inhaled insulin,
but is neither written by nor on behalf of Pfizer and Nektar Therapeutics, Exubera inhaled insulin's makers. All
trademark rights to Exubera are owned by Pfizer and/or Nektar Therapeutics, and no express or implied rights to such
are claimed by this blog.
Medical warning: No medical advice is offered by this blog. All persons reading this blog,
whether diabetic or not, must consult with their respective doctors and medical
professionals for diabetes advice and insulin treatment options. If you believe that you are experiencing a medical emergency, call 911 and/or seek medical help immediately.
Copyright © 2006 - 2007 BFLD, LLC
